EquiLend Awarded Global Data Provider and Regulatory Solution of the Year at the SFT Awards 2025

Posted on Posted in insight

Insight 10 JULY 2025 SFT AWARDS EquiLend Awarded Global Data Provider and Regulatory Solution of the Year 2025 at The Annual SFT Awards EquiLend is proud to announce two significant wins at the recent Securities Finance Awards 2025! 🏆 Global Data Provider of the Year 🏆 Regulatory Solution of the Year This recognition is an […]

The Purple Edition 19 | A Market’s Maturation: The Continued Growth of ETF Securities Finance

Posted on Posted in insight

Insight July 2025 The Purple A Market’s Maturation: The Continued Growth of ETF Securities Finance The long-term growth of the Exchange-Traded Fund (ETF) market is one of the most significant structural developments in modern finance. As ETFs have become foundational components of institutional portfolios, the ecosystem supporting them has matured in tandem. A key part […]

The Purple Edition 19 | Tariff Turbulence: How Trade Wars Reshaped Securities Lending in H1 2025

Posted on Posted in insight

Insight July 2025 The Purple Tariff Turbulence: How Trade Wars Reshaped Securities Lending in H1 2025 The securities lending market thrives on market volatility and since Trump took office the VIX volatility index peaked to levels not seen since March 2020, when COVID rattled the globe. According to President Trump, “Tariffs is the most beautiful […]

Market Flash on UNH

Posted on Posted in insight

UnitedHealth Group (TICKER: UNH) shares fell from $600 on April 11 to $275 as of May 15 erasing over $300 billion in market value as rising medical costs, regulatory pressures and a Department of Justice criminal investigation into possible Medicare fraud undermined investor confidence.

Market Flash on SMMT

Posted on Posted in insight

EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its squeeze score surging 43.0 points to 66 in just one month. With utilization approaching 78.98% and elevated borrow fees, short sellers are facing mounting pressure as positive clinical trial results drive momentum.